Industrial partners
HYpharm GmbH
HYpharm GmbH and a DZIF-funded consortium are collaborating on the production and development of the phage lysine protein HY-133, a highly innovative compound with specific activity against the bacterial pathogen Staphylococcus aureus. In June 2024, HY-133 entered the first phase of a clinical trial to assess the safety and toxicity of the new drug candidate in healthy volunteers.